Targeting BRD9 for Cancer Treatment: A New Strategy.
Targeting BRD9 for Cancer Treatment: A New Strategy.
复制标题
针对 BRD9 进行癌症治疗：一种新策略
DOI：
10.2147/ott.s286867
复制
发表时间：
2020
影响因子：
4
通讯作者：
Tang L
中科院分区：
文献类型：
--
作者：
Zhu X;Liao Y;Tang L
摘要溴结构域含蛋白9(BRD9)是新近发现的非典范屏障自整合因子(NcBAF)复合体的一个亚基，是溴结构域家族IV的成员之一。研究证实，BRD9通过调节肿瘤细胞的生长，在多种癌症类型中发挥致癌作用。BRD9的肿瘤生物学功能主要是通过其溴域介导的表观遗传修饰来实现的。溴域将ncBAF复合体招募到启动子以调节基因转录。本文综述了BRD9在肿瘤发生中的潜在作用机制，以及靶向BRD9用于癌症治疗的新策略。虽然BRD9的治疗潜力已经得到了一定程度的开发，但对BRD9的详细生物学机制的研究仍处于起步阶段。因此，靶向BRD9研究其生物学功能将是癌症诊断和治疗的一个有吸引力的工具，但它仍然是一个巨大的挑战。
Abstract Bromodomain-containing protein 9 (BRD9) is a newly identified subunit of the non-canonical barrier-to-autointegration factor (ncBAF) complex and a member of the bromodomain family IV. Studies have confirmed that BRD9 plays an oncogenic role in multiple cancer types, by regulating tumor cell growth. The tumor biological functions of BRD9 are mainly due to epigenetic modification mediated by its bromodomain. The bromodomain recruits the ncBAF complex to the promoter to regulate gene transcription. This review summarizes the potential mechanisms of action of BRD9 in carcinogenesis and the emerging strategies for targeting BRD9 for cancer therapeutics. Although the therapeutic potential of BRD9 has been exploited to some extent, research on the detailed biological mechanisms of BRD9 is still in its infancy. Therefore, targeting BRD9 to study its biological roles will be an attractive tool for cancer diagnosis and treatment, but it remains a great challenge.